(Bloomberg) -- Novavax Inc. shares surged after the company signed a $1.2 billion licensing agreement with Sanofi that includes commercializing a combined Covid-19 and flu shot. Novavax will ...

(Bloomberg) -- Novavax Inc. shares surged after the company signed a $1.2 billion licensing agreement with Sanofi that includes commercializing a combined Covid-19 and flu shot. Most Read from ...

Shares of Novavax surged after the company disclosed a $1.4 billion licensing deal with Sanofi. The stock was up 72% at $7.66 in premarket trading on Friday. Shares are on track to open in ...

Shares of Novavax jumped as much as 50% as Wall Street cheered a new multibillion-dollar deal with French drugmaker Sanofi that kicked off a dramatic turnaround for the struggling vaccine maker.

Struggling Novavax struck a $1.4 billion deal with Sanofi on Friday to commercialize its existing COVID-19 vaccine and develop a combined jab to protect against both the coronavirus and influenza ...

LONDON — Novavax, the beleaguered maker of a Covid-19 vaccine, just got a boost of its own. The French pharma company Sanofi on Friday said it had reached a licensing deal to sell Novavax’s ...

Novavax stock (NVAX) skyrocketed on Friday, nearly doubling on the news French drug and vaccine giant Sanofi (SNY) would invest $1.2 billion in a deal for Novavax's COVID-19 vaccine and take a ...

By Patrick Wingrove and Bhanvi Satija (Reuters) -Novavax on Friday said it had struck a licensing deal worth at least $1.2 billion with Sanofi for its COVID-19 vaccine in exchange for a stake that ...

Gaithersburg’s Novavax says it will have an updated Covid-19 vaccine ready after an FDA committee voted unanimously on the ...

Novavax (NASDAQ: NVAX) stock price has gone parabolic this year, making it one of the best-performing companies in New York.

Novavax (NVAX) shares are skyrocketing after the company announced a $1.2 billion deal with French drugmaker Sanofi (SNY). B. Riley Securities Managing Director & Group Head of Healthcare Research ...